Caisson’s patented HEPtune® technology improves the half-life of peptides, proteins, and small molecule drugs.
Caisson applies HEPtune® linker technology to enhanced antibody drug conjugates (ADCs).
Caisson’s HEPtune® technology engineered to improve the delivery of liposomes.
Caisson Biotech has developed a novel heparosan-based drug delivery platform, Heptune, to enhance the performance of therapeutics. Heparosan is a naturally occurring sugar polymer with low risk of toxicity and immunogenicity.
